What are the limitations of electronic drug interaction alerts and how should clinicians address potential gaps?

• A. Alerts are flawless and always followed.
• B. Alerts can be missed or ignored; clinicians should verify clinically, consult references, and involve pharmacists for review.
• C. Alerts cover all possible interactions; no further actions needed.
• D. Alerts replace the need for clinical judgment.

Answer: (B)

Electronic drug interaction alerts act as a safety net but come with important limits. They may miss clinically relevant interactions, and when they do fire, many alerts are not meaningful for a given patient because the risk depends on factors like dose, timing, organ function, other medications, and the patient’s overall condition. This can lead to alert fatigue, where clinicians start ignoring or overriding warnings, or to information overload that distracts from real safety threats. Alerts may also fail to capture over-the-counter products, supplements, or recently updated interactions if the system’s database isn’t current, so relying solely on automated warnings can leave gaps in patient protection.

To address these gaps, clinicians should review the full medication list in the context of the patient’s labs and conditions, and verify alerts against current references or drug interaction resources. Involve pharmacists or a medication safety team to review high-risk interactions and consider patient-specific factors before adjusting therapy. Document any overrides with clear rationale. Keep the decision-support system up to date and, when possible, tailor alert settings to reduce nuisance alerts while preserving important warnings. Ensure thorough reconciliation of all medications, including OTCs and supplements, and foster collaborative communication among the care team to maintain safe, individualized care.